NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
JRCT ID: jRCT1030210419

Registered date:10/11/2021

Study on the effect of disease modifiers on pain, fatigue and quality of life in patients with NMOSD

Basic Information

Recruitment status Pending
Health condition(s) or Problem(s) studiedNeuromyelitis Optica Spectrum Disorders
Date of first enrollment10/11/2021
Target sample size30
Countries of recruitmentJapan
Study typeObservational
Intervention(s)

Outcome(s)

Primary OutcomeEvaluation / measurement of motor function, ADL, disability, QOL, pain, fatigue, and depressive symptoms
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum>= 20age old
Age maximumNot applicable
GenderBoth
Include criteriaThe NMOSD diagnosis follows the diagnostic criteria of Wingerchuk et al. (Wingerchuk DM 2007, 2015). The subjects were patients who were diagnosed, treated, or newly diagnosed with neuromyelitis optica spectrum disorder (NMOSD) at our hospital from September 2020 to March 31, 2022. Patients who started administration of oral steroid humanized monoclonal antibody (Satralizumab, etc.) as a therapeutic intervention.
Exclude criteriaMinors (under 20 years old)

Related Information

Contact

Public contact
Name Ishii Kazuhiro
Address 1-1-1 Ten'noudai, Tsukuba, Ibaraki Ibaraki Japan 305-8575
Telephone +81-29-853-3204
E-mail kazishii@md.tsukuba.ac.jp
Affiliation University of Tsukuba
Scientific contact
Name Ishii Kazuhiro
Address 1-1-1 Ten'noudai, Tsukuba, Ibaraki Ibaraki Japan 305-8575
Telephone +81-29-853-3204
E-mail kazishii@md.tsukuba.ac.jp
Affiliation University of Tsukuba